Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 16/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887075 | 0.84 | HRH3 (0.58) | LTA4HKCNH2HRH3 | |
| SCHEMBL1889012 | 0.82 | LTA4H (0.60) | LTA4HDRD2 | |
| SCHEMBL1888687 | 0.81 | LTA4H (0.62) | LTA4HDRD2DRD4KCNH2 | |
| SCHEMBL1895734 | 0.78 | LTA4H (0.72) | LTA4HKCNH2 | |
| SCHEMBL9311044 | 0.78 | DRD2 (0.66) | LTA4HDRD2DRD4GRM2HRH3 | |
| SCHEMBL1889081 | 0.77 | LTA4H (0.65) | LTA4HKCNH2 | |
| SCHEMBL1887825 | 0.77 | LTA4H (0.55) | LTA4HDRD2DRD4GRM2KCNH2 | |
| SCHEMBL1889206 | 0.76 | LTA4H (0.78) | LTA4HKCNH2 | |
| SCHEMBL15282318 | 0.76 | LTA4H (0.58) | LTA4HKCNH2 | |
| SCHEMBL2168470 | 0.74 | LTA4H (0.79) | LTA4HKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885DRD2 3887/4885DRD4 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.